News
(2)April 2026
Rapport Therapeutics Reports Cash Runway and RAP-219 Trial Progress
# 🧾 What This Document Is This is Rapport Therapeutics' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" and "state of the union" combined into one document, sent directly to its investors. It's designed to give a comprehensive, investor-friendly overview
RAPP reports 68% sustained seizure reduction with RAP-219 follow-up data
# 📄 What This Document Is 📰 This filing is a detailed summary of results presented at a major medical conference, the 2026 American Academy of Neurology (AAN) Annual Meeting. It's not a formal SEC filing, but an official presentation of scientific data about the company's lead drug, RAP-219. Bec
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.